Featured News
Recent GW School of Medicine and Health Sciences faculty, staff, and student accomplishments.
The GW clinical enterprise — GW Hospital, the GW Medical Faculty Associates, and the GW School of Medicine and Health Sciences— are reaching out to newly vaccinated members...
The George Washington University (GW), in collaboration with Whitman Walker Institute (WWI), was selected by the National Institute of Allergy and Infectious Diseases (NIAID) to receive an $8.4 million, seven‐year award as part of a significant...
Health and Human Services (HHS) Secretary Alex Azar, U.S. Surgeon General Jerome Adams, and D.C. Mayor Muriel Bowser (D) joined George Washington University (GW) clinical enterprise leadership as five members of the GW health care workforce...
In the first two weeks since the Pfizer-BioNTech vaccine, and later the Moderna vaccine, received Emergency Use Authorization from the U.S. Food and Drug Administration, health care workers and others have begun receiving vaccinations for COVID-...
Congratulations to all our students, alumni, faculty, and staff this month on their success. The items below highlight the breadth of achievement and expertise that can be found at the George Washington University School of Medicine and Health...
Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, said during an exchange with students at the George Washington University School of Medicine and Health Sciences that one way to combat the politicization...
Images that highlight the beauty and breadth of biomedical research and a passion for science at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) were on display in the annual SMHS Art of Science contest.
The George Washington University (GW) School of Medicine and Health Sciences (SMHS) has received a $700,000 grant from the Commonwealth of Virginia to implement an innovative educational project in the life sciences and expand regional job...
As news emerges that COVID-19 vaccine trials from U.S. pharmaceutical corporations Pfizer and Moderna are showing, in preliminary data, high-efficacy rates, a new question is being asked: What comes next?
